GlassScriptPhysician profile
Elam Safi
NPI 1780646141
$1,454.40
in general payments reported to CMS, 2019-2025
18 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $91.67 · 2021: $11.51 · 2022: $13.99 · 2023: $42.90 · 2024: $119 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $323.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $291.87 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.40 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $88.63 | 2019-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $78.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $70.97 | 2019 | |
| Astellas Pharma US INC | $66.30 | 2019-2023 | Veozah |
| Allergan, INC. | $60.14 | 2019 | |
| Lilly USA, LLC | $50.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $48.14 | 2019 | |
| Novo Nordisk INC | $47.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.81 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.31 | 2019 | |
| Abbvie INC. | $38.74 | 2022-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.22 | 2019 | |
| Sumitomo Pharma America, INC. | $14.52 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elam Safi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.